本帖最后由 老马 于 2012-1-13 21:20 编辑
+ X) a& ]& a7 ]' d+ l4 }* o: H0 q" F" ]) `; N7 G8 C- K. J
爱必妥和阿瓦斯丁的比较
) M& A' Q# ^) K' Z
9 W, i# j c: b, y* v" \
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/! N# E- l8 M- j* P2 ]( l7 E# a
3 g$ m1 N; l$ q* J
" O8 z/ G% U6 I8 e' ^) Y
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
/ x& C. m7 y" D7 B==================================================
! u1 |* D+ R- ~+ U$ COverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
& Y% K: B' L( e5 Y M# YPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
! l# r& m: Q# ^2 E! hResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
. T/ l/ T, Y: F0 A
|